38780-36-8

Basic information

• Product Name: dichlorobis(cyclopentylamine)platinum
• Synonyms: dichlorobis(cyclopentylamine)platinum;cis-Dichlorobis(cyclopentylamine)platinum;Nsc170898;Platinum, dichlorobis(cyclopentanamine)-, (sp-4-2)-;Uc 51
• CAS NO: 38780-36-8
• Molecular Formula: C₁₀H₂₂Cl₂N₂Pt
• Molecular Weight: 436.27908
• EINECS: 254-125-2
• Mol File: 38780-36-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 110°C at 760 mmHg
• Flash Point: 17.2°C
• Appearance: /
• Vapor Pressure: 24.2mmHg at 25°C
• CAS DataBase Reference: dichlorobis(cyclopentylamine)platinum(CAS DataBase Reference)
• NIST Chemistry Reference: dichlorobis(cyclopentylamine)platinum(38780-36-8)
• EPA Substance Registry System: dichlorobis(cyclopentylamine)platinum(38780-36-8)

Safety Data

• Hazardous Substances Data: 38780-36-8(Hazardous Substances Data)

Usage

Safety Profile

Moderately toxic byintraperitoneal route. Questionable carcinogen with experimental carcinogenic data. Mutation data reported. When heated todecomposition it emits very toxic fumes of Cl- and NOx.

InChI:InChI=1/2C5H10N.2ClH.Pt/c2*6-5-3-1-2-4-5;;;/h2*5-6H,1-4H2;2*1H;/q2*-1;;;+4/p-2/r2C5H10N.Cl2Pt/c2*6-5-3-1-2-4-5;1-3-2/h2*5-6H,1-4H2;/q2*-1;+2

Upstream product

• 71360-93-5 cis-[diiodobis(cyclopentylamino)platinum(II)] 
• 38780-36-8 cis-dichloro(cyclopentylamine)platinum 
• 850940-74-8 trans-[diiodobis(cyclopentylamino)platinum(II)] 
• 10025-99-7 potassium tetrachloroplatinate(II) 
• 1003-03-8 Cyclopentamine 

Downstream Products

• 56846-69-6 trans-{Pt(cyclopentylNH₂)2Cl₂} 
• 176705-96-7 C₁₀H₂₄Cl₂N₂O₂Pt 

Relevant articles and documents

Molecular interaction fields vs. quantum-mechanical-based descriptors in the modelling of lipophilicity of platinum(iv) complexes

We report QSAR calculations using VolSurf descriptors to model the lipophilicity of 53 Pt(iv) complexes with a diverse range of axial and equatorial ligands. Lipophilicity is measured using an efficient HPLC method. Previous models based on a subset of these data are shown to be inadequate, due to incompatibility of whole molecule descriptors between carboxylato and hydroxido ligands. Instead, the interaction surfaces of complexes with various probes are used as independent descriptors. Partial least squares modelling using three latent variables results in an accurate (R2 = 0.92) and robust model (Q2 = 0.87) of lipophilicity, that moreover highlights the importance of size and hydrophobicity terms and the modest relevance of hydrogen bonding.

Dichlorobis(cycloalkylamine)platinum(II) Complexes. Structure Activity Relationship on the Human MDA-MB-231 Breast Cancer Cell Line

The syntheses of dichlorobis(cycloalkylamine)platinum(II) complexes with cis and trans cycloalkylamine ligands are described.The distinction between cis and trans isomers was achieved by (1)H-NMR spectroscopy.The antitumor activity was determined on the cell proliferation of the human MDA-MB-231 breast cancer cell line during long-term drug exposure.The complexes with small cycloalkylamine ligands (3-6) were inferior, those with large cycloalkylamine ligands were comparable (7) or superior (8) to cisplatin.Surprisingly, the cis/trans isomers 7/9 and 8/10 were equally active.All cycloalkylamine ligands were inactive.IR-spectroscopic studies showed that the size of the cycloalkylamine ring does not lead to significant differences in the Pt-Cl binding strength.Therefore it is assumed that the markedly stronger antitumor activity of the higher homologues, 7-10, is not the result of a faster reaction with binucleophiles such as DNA.A possible explanation of the high activity of 7-10 is the strong lipophilicity of the complexes.This assumption was confirmed by toxicity tests against confluent cultures. Key words: cis- and trans-Dichlorobis(cycloalkylamine)platinum(II) complexes; antitumor activity; MDA-MB-231 breast cancer cell line.